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Although paroxysmal atrial fibrillation (AF) is known to be initiated by rapid firing of pulmonary veins (PV) and non-PV
triggers, the crucial role of cardiac autonomic nervous system (ANS) in the initiation and maintenance of AF has long been
appreciated in both experimental and clinical studies. The cardiac intrinsic ANS is composed of ganglionated plexi (GPs), located
close to the left atrium-pulmonary vein junctions and a vast network of interconnecting neurons. Ablation strategies aiming for
complete PV isolation (PVI) remain the cornerstone of AF ablation procedures. However, several observational studies and few
randomized studies have suggested that GP ablation, as an adjunctive strategy, might achieve better clinical outcomes in patients
undergoing radiofrequency-based PVI for both paroxysmal and nonparoxysmal AF. In these patients, vagal reactions (VR) such
as vagally mediated bradycardia or asystole are thought to reflect intrinsic cardiac ANS modulation and/or denervation. Vagal
reactions occurring during cryoballoon- (CB-) based PVI have been previously reported; however, little is known on resulting
ANS modulation and/or prevalence and significance of vagal reactions during PVI with the CB technique. We conducted a review
of prevalence, putative mechanisms, and significance of VR during CB-based PVI.
1. Introduction
Paroxysmal atrial fibrillation (AF) is known to be initiated by
rapid firing of pulmonary veins (PVs) and non-PV triggers
[1, 2]. In parallel, the crucial role of cardiac autonomic
nervous system (ANS) in the initiation and maintenance of
atrial fibrillation (AF), especially paroxysmal AF, has long
been appreciated in both experimental and clinical studies
[3–8]. Indeed, stimulation of cardiac ANS may induce AF
in both animals and humans [3–8]. Conversely, parasympa-
thetic nerve denervation has been demonstrated to prevent
induction of AF in canine study [9, 10].
The cardiac intrinsic ANS is composed of ganglionated
plexi (GPs) and a vast network of interconnecting neurons
[7, 11]. The major left atria GPs are located in epicardial
fat pads at 4 preferential locations close to the left atrium-
pulmonary vein (PV) junctions: superior left GP, inferior
left GP, anterior right GP, and inferior right GP [7, 11]. The
ganglionated plexi act as an integration and interconnection
system between the cardiac extrinsic ANS nerves, originating
from the central ANS and reaching the heart through the
mediastinum, and the rest of the intrinsic cardiac ANS, the
so-called “atrial neural network” [7, 11].
Ablation strategies targeting the PV and aiming for
complete PV isolation (PVI) remain the cornerstone of AF
ablation procedures [12]. Radiofrequency is the conventional
energy source used by cardiac electrophysiologists to achieve
PVI [12]. However, the cryoballoon (CB) technique has also
been validated as a safe and valuable tool in order to achieve
PVI and represents an alternative to radiofrequency [12–18].
Several observational studies and few randomized studies
have suggested that GP ablation, as an adjunctive strategy,
might achieve better clinical outcomes in patients under-
going radiofrequency-based PVI for both paroxysmal and
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nonparoxysmal AF [19–22]. In these patients, vagal reactions
(VR) such as vagally mediated bradycardia or asystole are
thought to reflect intrinsic cardiac ANS modulation and/or
denervation [19–22]. Heart rate variability (HRV) has been
suggested as a simple and effective noninvasive tool for
evaluation ofANS activity [6, 8, 19, 22]. Reduction ofHRVhas
been proposed as an indicator for cardiac ANSmodulation in
patients undergoing PV radiofrequency ablation [6, 8, 19, 22].
Vagal reactions occurring during CB-based PVI have
been previously reported; however, little is known on result-
ing ANS modulation and/or prevalence and significance of
VR during PVI with the CB technique. We conducted a
review of prevalence, putative mechanisms, and significance
of VR during CB-based PVI.
2. Cardiac Autonomic Denervation during
Radiofrequency Pulmonary Vein Ablation
Ganglionated plexi ablation aiming for modulation/
denervation of the intrinsic cardiac ANS has been proposed
as an adjunctive strategy for radiofrequency catheter
ablation of paroxysmal and nonparoxysmal AF [19–22].
Ganglionated plexi locations may be identified during AF
ablation by endocardial high frequency electric stimulation
at sites exhibiting VR (i.e., bradycardia below 40 bpm or
asystole) [19, 20, 22]. Thereafter, these sites, always showing
complex fractionated atrial activity during AF, are targeted
during endocardial radiofrequency catheter ablation with
abolishment of VR as the ablation endpoint [12, 19–22].
Anatomically guided ablation of GP has been demonstrated
to be noninferior to the high frequency pacing strategy,
probably because cardiac GPs exhibit only small variations
in location [11]. In fact, GP ablation often occurs during
wide circumferential PV ablation as a “collateral damage” of
procedures aiming for PVI with large antral linear lesions
[19, 20, 23]. In an observational study, Pappone et al. reported
VR in 102/297 patients (34.3%) during wide circumferential
PVI [19]. They indicated that VR mostly occurred during
radiofrequency application at the cranial junction of the
left superior PV and the left atrium (in 95% of patients
with VR) and at the posteroinferior junction between the
left inferior PV and left atrium (71 patients, 70%) [19].
These sites are known to be the locations of 2 of 4 major
left atrial GPs [7, 11]. Additionally, intrinsic cardiac ANS
denervation, assessed by reduction of HRV, was observed in
up to one-third of patients undergoing wide circumferential
PVI but was limited for a 3-month period following index
procedure [19]. However, when RF lesions were created using
an open irrigation tip catheter, cardiac ANS modulation
was maintained 1 year after the index procedure [24, 25].
In these aforementioned studies, cardiac ANS modulation
was associated with lower AF recurrence [19, 24, 25]. When
added to PVI, RF lesions applied to the GPs significantly
improved outcomes in randomized study by Katritsis et al.
[21]. After a 2-year follow-up, freedom from AF or atrial
tachycardia was of 56% and 74% in PVI alone and PVI + GP
ablation groups, respectively [21]. Conversely, GP ablation
alone conferred a worse outcome than PVI alone, where it
was shown that freedom from AF or atrial tachycardia was
48% and 56% in GP ablation and PVI groups, respectively
(𝑝 = 0.001 for comparison between groups) [21].
3. Cardiac Autonomic Denervation
during Cryoballoon-Based Pulmonary
Vein Ablation
The CB technique targets the PVs and adjacent myocardium
with the aim of obtaining a complete PVI [12–18]. It is
achieved for a very high proportion of patients after a single
procedure, conferring a very acceptable outcome [13–18].
Little is known regarding intrinsic cardiac ANS mod-
ulation during CB-based PVI. Oswald et al. were the first
to investigate the effect on ANS when applying cryoenergy
at the PV ostia, although it should be mentioned that the
PVIs were performed with the first generation CB (Arctic
Front, Cryocath, Montreal, Canada) [26]. Similarly to RF
studies, the authors used HRV as a marker of ANS modu-
lation. Although the study sample was small (14 paroxysmal
AF patients), they demonstrated that AF cryoablation was
associated with significant ANS modulation. Indeed, 12 out
of 14 patients (86%) presented with significant decrease in
HRV after the cryoablation procedure. Five patients (36%)
required temporary pacing for symptomatic intraprocedural
bradycardia<40 bpmor asystole but the 3 largest HRV reduc-
tions occurred in patients without VR during the procedure.
Interestingly the authors reported that the 2 patients that
did not show HRV decrease were free of AF recurrence
thereafter. Five patients out of 12 with decrease in HRV
(41.7%) experienced AF recurrence during follow-up. The
authors hypothesized that VR might be induced by either
stretch of the left atrial tissue, direct damage to cardiac nerve
tissue during the thawing phase, or hyperemia at the CB-
tissue interface.
The second generation of CB (Arctic Front Advance,
Medtronic) has been redesigned to enhance lesion quality.
The goal was to create transmural contiguous lesions in
order to achieve durable PVI. The number of refrigerant
injection ports has been increased from 4 to 8 with a
more distal orientation, resulting in higher refrigerant flow
(for Arctic Front Advance 28mm) that improves balloon
cooling uniformity with lower temperature at the CB surface.
Compared to the first generation CB, Arctic Front Advance
CB has been demonstrated to increase single-shot PVI rate
and decrease time to PVI as well as having shorter procedure
and radiation exposure times [15, 16]. Importantly, freedom
from AF at mid-term follow-up appeared higher with the
Arctic Front Advance CB [17, 18]. Thanks to these technical
features, VR might be expected to occur more often with the
second generation of CB.
Yorgun et al. specifically studied the impact of VR during
PV cryoablation on clinical outcomes in 145 patients with
paroxysmal (81%) or persistent drug-refractory AF treated
with the second generation CB [27]. After a 17-month
follow-up period, 119/145 patients (82.1%) were free from
AF recurrence. Notably, they reported a high prevalence of
VR (40.7%), characterized as significant bradycardia and/or
hypotension during CB application at the PVs. Intravenous
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atropine administration, to treat symptomatic heart rate drop
below 40 bpm or pauses, was required in up to 33.1% of
patients. Interestingly, VR or the need of atropine adminis-
tration was more frequent in patients without AF recurrence
after the end of follow-up (46.2% versus 15.4%, 𝑝 = 0.004
and 38.7% versus 7.7%, 𝑝 = 0.002, resp.). Using a univariate
Cox proportional hazard regression analysis, Yorgun et al.
found that VR and requirement of atropine administration
or cardiac pacing for severe bradycardia decreased the risk of
AF recurrence. Using amultivariate Cox proportional hazard
regression analysis, the authors demonstrated that the need of
atropine administration was an independent predictor of AF
recurrence in patients undergoing PVIwith the CB technique
(HR: 0.064; 95%CI: 0.008–0.48,𝑝 = 0.008) while VRwas not
(HR: 2.59; 95% CI: 0.56–12.05, 𝑝 = 0.225) [27]. Otherwise, in
their discussion, Yorgun et al. hypothesized that the use of the
bigger 28mm CB might generate more VR compared to the
23mm CB due to more antral cryolesions location. Finally,
unanswered question underlined by the authors is whether
VR, as a clue for ANS modification, might be considered
as a potential end-point of CB-based PVI procedures or
only represents a marker of collateral damage during PV
cryoablation.
Aytemir et al. recently tried to define the predictive factors
of late AF recurrence with the current CB when compared
to the first generation CB [28]. They reported a series of 306
consecutive patients (mean age of 55.3 ± 10 years) presenting
with drug-refractory symptomatic paroxysmal (80.7%) or
persistent AF. They underwent PVI attempt using either the
first generation CB (𝑛 = 197) or the second generation CB
(𝑛 = 109 patients). Main conclusion was that the use of the
second generation CB resulted in lower late AF recurrence
rate. They also demonstrated that both intraprocedural VR
and second generation CB use were associated with fewer
late AF recurrences. Furthermore, it was found that VR
were more frequently observed with the second generation
CB compared with the first generation CB (50.4% versus
38.1%; 𝑝 = 0.036). Also, systematic use of the largest 28mm
CB that resulted in more antral CB positioning compared
to the 23mm model might have explained, by itself, the
higher prevalence of VR. Multivariate Cox proportional
hazard regression analysis related to the late AF recurrence
following single cryoablation identified left atrium diameter,
early recurrence, and Artic Front Advance CB use as the
only predictive factors of late AF recurrence. Vagal reactions
tended to be predictive for lower late AF recurrence, but did
not reach statistical significance (HR: 0.574; 95% CI: 0.335–
1.002, 𝑝 = 0.055).
In the three aforementioned studies, several findings
are reported. First, the occurrence of VR during CB-based
PVI is reported to be frequent, ranging from 36% to 50%,
which is comparable to RF studies, and higher with the
second generation CB [19, 26–28]. Secondly, VR during
PV cryoablation with the first generation CB is considered
as a marker of intrinsic ANS modification but analysis of
postablation HRV showed that this latter lasts no more than
3 months [26]. It should be mentioned that the second
generation CB, resulting inmore extensivemyocardial injury,
might have a more sustained impact on postablation HRV.
Finally, intraprocedural VR are associated with lower rates of
AF recurrence [24–26]. Nevertheless, some data are lacking
to better characterize VR during PVI with the CB technique.
Also, little is known regarding clinical characteristics of
patients presenting VR during PV cryoablation. Similarly,
data on HRV following PV cryoablation with the second
generation CG or putativemechanisms of improved outcome
for patients experiencing VR during CB-based PVI are
lacking.
In our practice, we currently use theCB technique for PVI
in paroxysmal AF patients for nearly 8 years. In our expe-
rience of 980 PV cryoablation procedures performed in our
institution (280 and 700 procedures with the first and second
generation of CB, resp.) and although we did not specifically
investigate the role of VR during PV cryoablation as a predic-
tive factor for AF recurrence, we found a lower prevalence of
vagally mediated bradycardia during CB application, about
5 to 10% (unpublished data). Even lower prevalence of VR
was observed with the first generation CB compared with
the second generation CB. Vagally mediated bradycardia was
transient, was self-limited, and required exceptionally tempo-
rary pacing or atropine administration. Similar to previous
studies, we noticed VR during the CB thawing phase or at
time of CB deflation [26–28]. Vagally-mediated bradycardia
was systematically related to sinus bradycardia or sinus arrest,
exclusively following CB application at the left-sided PVs
(Figure 1).Wenever observed transient atrioventricular block
and/or VR following cryoapplication at the right-sided PVs.
This fact may be explained by the nervous connections
between the left-sidedGPs and the sinus node, whereas right-
sided GPs are mainly connected with the atrioventricular
node [7, 11]. Rarely, VR might occur during CB placement
at the PV ostium and during PV occlusion attempt. This
maneuver may result in significant left atrial stretch, known
to be a putative mechanism for VR [26]. More importantly,
we pointed out that VR was reproducible after “bonus”
cryoapplication, that is, following additional CB application
after achievement of acute PVI. Vagal reactions were neither
attenuated nor enhanced after successive CB applications in
our experience. Therefore, we think that the reproducibility
of VR during “bonus” cryoapplication strongly rejects the
hypothesis of intrinsic ANSmodification/denervation during
PV cryoablation. We believe that VR during PV cryoablation
should rather be considered as a marker of intrinsic cardiac
ANS stimulation rather than a marker of intrinsic cardiac
ANS modulation/denervation. In the same line, RF studies
have shown progressive reduction of intensity of VR during
CPVI with successful ANS denervation [19–23]. On the
other hand, we think that VR during CB-based PVI is a
highly specific marker of the transmurality of the cryolesion
comparable to that reported with phrenic nerve palsy at the
right-sided PVs [29]. Finally, ANS reinnervation might be a
putative mechanism for both recovery of ANS activity and
recurrence of atrial arrhythmia [30, 31].
4. Conclusion
Vagal reactions during CB-based PVI are not infrequent.
Some authors consider VR during PV cryoablation as a
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Figure 1: Vagally mediated asystole during thawing phase of the cryoballoon after a 180-second application at the left superior pulmonary
vein ostium in a patient with drug-refractory paroxysmal AF. Note that the progressive sinus rhythm rate decreases followed by a 7.6-second
asystole. Sinus rhythm resumed thereafter. Time to pulmonary vein isolation was 26 seconds and CB temperature at PVI time was −27∘C.
Minimal CB temperature reached was −52∘C. After 18 months of follow-up, the patient was free from any atrial arrhythmia recurrence. SC:
coronary sinus; VP: pulmonary vein.
marker of ANS modification. Due to the temporary effect
of PV cryoablation on ANS activity with the first generation
CB (assessed by analysis of HRV with gradual recovery of
normal HRV at 3 months), questions remain regarding the
mechanism of improved outcome for patients experiencing
VR during CB-based PVI. Larger studies conducted with the
second generation CB and achieving long-term follow-up are
needed to validate this hypothesis and to confirm the putative
mechanisms.
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